PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces the achievement of the reserved capital increase and the payment of the €1 million milestone, as provided in the commercialization agreement signed with the Therabel Group for Loramyc® in Europe.
